The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Condition	Treatment or Intervention	Phase
Major Depressive Disorder Depressive Disorder not otherwise specified (NOS) Dysthymic Disorder	Drug: fluoxetine  Drug: sertraline  Drug: citalopram  Drug: escitalopram  Drug: buproprion  Drug: mirtazapine  Drug: venlafaxine  Drug: lithium  Behavior: Cognitive Behavioral Therapy	Phase II Phase III

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Ages Eligible for Study:  12 Years   -   18 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• At least one suicide attempt or interrupted attempt within the past 45 days
• Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Ben Vitiello, MD      301.443.4283    bvitiell@mail.nih.gov

Maryland
      Johns Hopkins University, Baltimore,  Maryland,  21287,  United States; Recruiting
New York
      Columbia University at the New York State Psychiatric Institute, New York,  New York,  10032,  United States; Recruiting
      New York University Child Study Center, New York,  New York,  10016,  United States; Recruiting
North Carolina
      Duke University Medical Center, Durham,  North Carolina,  27705,  United States; Recruiting
Pennsylvania
      University of Pittsburgh - Western Psychiatric Institute and Clinic, Pittsburgh,  Pennsylvania,  15213,  United States; Recruiting
Texas
      University of Texas, Southwestern Medical Center, Dallas,  Texas,  75235,  United States; Recruiting

Study chairs or principal investigators

Laurence Greenhill, MD,  Study Chair

Study ID Numbers:  1U10MH66762-01
Record last reviewed:  August 2004
Record first received:  March 24, 2004
ClinicalTrials.gov Identifier:  NCT00080158
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-27